Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 10/20 | 0.45 |
| ▸ | JAK1 | P23458 | 10/20 | 0.45 |
| ▸ | TYK2 | P29597 | 10/20 | 0.45 |
| ▸ | JAK3 | P52333 | 10/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22909073 | 0.89 | JAK2 (0.46) | HSD17B10JAK2JAK1TYK2JAK3 | |
| SCHEMBL22908950 | 0.89 | JAK2 (0.48) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL22909077 | 0.88 | JAK2 (0.43) | HTTHSD17B10JAK2JAK1TYK2 | |
| SCHEMBL29663880 | 0.88 | SIRT2 (0.44) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL22908904 | 0.88 | SIRT2 (0.44) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL24772450 | 0.87 | KDM4E (0.51) | HSD17B10JAK2JAK1TYK2JAK3 | |
| SCHEMBL22908954 | 0.87 | JAK2 (0.44) | HSD17B10JAK2JAK1TYK2JAK3 | |
| SCHEMBL24771133 | 0.86 | KDM4E (0.49) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL24771130 | 0.86 | KDM4E (0.49) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL24771860 | 0.85 | SIRT2 (0.42) | HTTHSD17B10JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384801-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | CTXT PTY LTD. (AU) | 2025-08-12 | — | — | US | disclosed |
| EP-3999185-B1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT PTY LTD (AU) | 2023-08-30 | — | — | EP | disclosed |
| EP-3999185-B1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT PTY LTD (AU) | 2023-08-30 | — | — | EP | disclosed |
| US-20220389032-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT PTY LTD. (AU) | 2022-12-08 | — | — | US | disclosed |
| US-20220389032-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT PTY LTD. (AU) | 2022-12-08 | — | — | US | disclosed |
| EP-3999185-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT Pty Limited (AU) | 2022-05-25 | — | — | EP | disclosed |
| WO-2021009365-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT PTY LIMITED (AU) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384801-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | STING1, CGAS, MAVS | HTT 4403/4885HSD17B10 4526/4885JAK2 1293/4885 |
| US-20220389032-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | STING1, CGAS, MAVS | HTT 4403/4885HSD17B10 4526/4885JAK2 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.